ATE167630T1 - Bahandlung von tumoren mit neutrophischen faktoren und hemmern der zellproliferation - Google Patents

Bahandlung von tumoren mit neutrophischen faktoren und hemmern der zellproliferation

Info

Publication number: ATE167630T1
Authority: AT; Austria
Prior art keywords: cell proliferation; neuroblastoma cells; tumors; treatment; proliferation inhibitors
Prior art date: 1992-08-27

Application number

AT93920383T

Other languages

English (en)

Inventor

Patrizia Lopresti

Wojciech Poluha

Dorota K Poluha

Alonzo H Ross

Original Assignee

Worcester Found Ex Biology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-27

Filing date

1993-08-26

Publication date

1998-07-15

1993-08-26 Application filed by Worcester Found Ex Biology filed Critical Worcester Found Ex Biology

1998-07-15 Application granted granted Critical

1998-07-15 Publication of ATE167630T1 publication Critical patent/ATE167630T1/de

Links

230000004663 cell proliferation Effects 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title 1
108010025020 Nerve Growth Factor Proteins 0.000 abstract 4
206010029260 Neuroblastoma Diseases 0.000 abstract 4
102000007072 Nerve Growth Factors Human genes 0.000 abstract 3
239000003900 neurotrophic factor Substances 0.000 abstract 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 abstract 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 abstract 1
102000015336 Nerve Growth Factor Human genes 0.000 abstract 1
NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 abstract 1
SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 abstract 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
229960001330 hydroxycarbamide Drugs 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
231100000636 lethal dose Toxicity 0.000 abstract 1
229940053128 nerve growth factor Drugs 0.000 abstract 1
229940104230 thymidine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Psychology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT93920383T 1992-08-27 1993-08-26 Bahandlung von tumoren mit neutrophischen faktoren und hemmern der zellproliferation ATE167630T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/936,923 US5387520A (en)	1992-08-27	1992-08-27	Treatment of tumor cells in vitro with neurotrophic factors and cell proliferation inhibitors

Publications (1)

Publication Number	Publication Date
ATE167630T1 true ATE167630T1 (de)	1998-07-15

Family

ID=25469222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93920383T ATE167630T1 (de)	1992-08-27	1993-08-26	Bahandlung von tumoren mit neutrophischen faktoren und hemmern der zellproliferation

Country Status (10)

Country	Link
US (1)	US5387520A (de)
EP (1)	EP0658117B1 (de)
JP (1)	JPH08500836A (de)
AT (1)	ATE167630T1 (de)
CA (1)	CA2141935A1 (de)
DE (1)	DE69319346T2 (de)
DK (1)	DK0658117T3 (de)
ES (1)	ES2117717T3 (de)
GR (1)	GR3027661T3 (de)
WO (1)	WO1994005315A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5789187A (en) *	1992-08-27	1998-08-04	Worcester Foundation For Experimental Biology	Identification of differentiation factor receptors which inhibit the tumorigenicity of neuroblastoma cells in a ligand-independent manner
EP0632008B1 (de) *	1993-06-01	1998-02-04	Ono Pharmaceutical Co., Ltd.	Pentansäurederivate
JPH0856655A (ja) *	1994-08-16	1996-03-05	Frontier:Kk	細胞致死剤および細胞死抑制剤
US5648220A (en) *	1995-02-14	1997-07-15	New England Medical Center Hospitals, Inc.	Methods for labeling intracytoplasmic molecules
WO2007105218A2 (en) *	2006-03-14	2007-09-20	Yeda Research And Development Co. Ltd.	Composition and method for brain tumor therapy
CN114732839A (zh) *	2022-01-25	2022-07-12	长春中医药大学	人参总皂苷碳纳米点在制备抗神经母细胞瘤、抑制神经母细胞瘤细胞药物制剂领域中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO157136C (no) *	1982-11-10	1988-01-27	Ici Plc	Analogifremgangsmaate for fremstilling av terapeutisk aktive homocykliske derivater.
US5008252A (en) *	1987-03-20	1991-04-16	The University Of North Carolina At Chapel Hill	Process for inhibiting herpes simplex virus-specified thymidine kinase

1992
- 1992-08-27 US US07/936,923 patent/US5387520A/en not_active Expired - Fee Related
1993
- 1993-08-26 JP JP6507332A patent/JPH08500836A/ja active Pending
- 1993-08-26 DK DK93920383T patent/DK0658117T3/da active
- 1993-08-26 AT AT93920383T patent/ATE167630T1/de not_active IP Right Cessation
- 1993-08-26 EP EP93920383A patent/EP0658117B1/de not_active Expired - Lifetime
- 1993-08-26 WO PCT/US1993/008088 patent/WO1994005315A1/en not_active Ceased
- 1993-08-26 ES ES93920383T patent/ES2117717T3/es not_active Expired - Lifetime
- 1993-08-26 DE DE69319346T patent/DE69319346T2/de not_active Expired - Fee Related
- 1993-08-26 CA CA002141935A patent/CA2141935A1/en not_active Abandoned
1998
- 1998-08-17 GR GR980401840T patent/GR3027661T3/el unknown

Also Published As

Publication number	Publication date
DE69319346T2 (de)	1999-04-01
EP0658117A1 (de)	1995-06-21
DK0658117T3 (da)	1999-02-01
US5387520A (en)	1995-02-07
GR3027661T3 (en)	1998-11-30
ES2117717T3 (es)	1998-08-16
CA2141935A1 (en)	1994-03-17
EP0658117B1 (de)	1998-06-24
JPH08500836A (ja)	1996-01-30
DE69319346D1 (de)	1998-07-30
WO1994005315A1 (en)	1994-03-17

Legal Events

Date	Code	Title	Description
1999-03-15	UEP	Publication of translation of european patent specification
2000-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
UA74325C2 (uk)	2005-12-15	ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ р38, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇХ МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ ЗА ЇХ ДОПОМОГОЮ
TR199902194T2 (xx)	2000-06-21	+p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
ATE281840T1 (de)	2004-11-15	Behandlung von diarrhoe
DE69233195D1 (de)	2003-10-16	Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose
EA199900464A1 (ru)	2000-02-28	Способы и композиции для стимуляции роста невритов
DE68927479D1 (de)	1997-01-02	Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
ATE295889T1 (de)	2005-06-15	Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
DE69734100D1 (de)	2005-10-06	Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate-aufnahme
AU2689195A (en)	1995-12-05	Methods of inducing gene expression by ionizing radiation
NZ223549A (en)	1989-10-27	Macromolecular antitumour compositions containing platinum
DK0831812T3 (da)	2006-07-17	Fremgangsmåder og præparater til stimulering af neuritvækst
DE69328474D1 (de)	2000-05-31	Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
ATE63748T1 (de)	1991-06-15	Enzymwiderstandsfaehige immunomodulatorische peptide.
ATE190623T1 (de)	2000-04-15	Verwendung von steroiden zur inhibierung von angiogenesis
ATE145556T1 (de)	1996-12-15	Verwendung von interleukin-4 zur behandlung der festen tumoren
ATE167630T1 (de)	1998-07-15	Bahandlung von tumoren mit neutrophischen faktoren und hemmern der zellproliferation
ATE250427T1 (de)	2003-10-15	Zusammensetzungen und deren verwendung zur hemmung von angiogenese
Ikai et al.	1983	Phosphorylation of keratin polypeptides
NO951277L (no)	1995-04-03	Desulfatohirudin med höy molekylvekt
Geetha et al.	1980	An in vitro protein-synthesizing system with isolated chloroplasts of Sorghum vulgare. An alternate assay system for exogenous template RNA.
KR940702380A (ko)	1994-08-20	종양 및 육종의 치료 방법(A Method for the treatment of Tumours and Sarcomas)
AU4367600A (en)	2001-01-22	Dsp-3 dual-specificity phosphatase
ATE365718T1 (de)	2007-07-15	Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
AU578125B2 (en)	1988-10-13	Pyrazine diazohydroxide compounds
DE69433851D1 (de)	2004-07-22	Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv